Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients - Related Studies

Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients

This study has been completed.

Study NCT00204789. Last updated on December 21, 2007. Information provided by University of Wisconsin, Madison

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Post-Solid Organ Transplant
		Skin Neoplasms

2	More general conditions related to this trial
		Neoplasms
		Neoplasms by Site
		Skin Diseases

3	Interventions listed in this trial
		Difluoromethylornithine

4	Additional drug interventions recognized in this trial
		Eflornithine

5	More general drug interventions related to this trial
		Anti-Infective Agents
		Antineoplastic Agents
		Antiparasitic Agents
		Antiprotozoal Agents
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Therapeutic Uses
		Trypanocidal Agents

6	Sponsors listed in this trial
		University of Wisconsin, Madison